NCT04119102招募中4 期
Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.
Psoriasis Treatment Center of Central New Jersey1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2019年10月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Body surface area improvement
研究概览
简要总结
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
详细描述
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adult ≥ 18 years of age;
- •Diagnosis of chronic plaque-type
- •Psoriasis affecting 2%-10% BSA
- •Patient is being treated with biologic therapy for a minimum of 24 weeks
- •Able and willing to give written informed consent prior to performance of any study-related procedures
排除标准
- •Psoriasis affecting ˂2% or >10% BSA
- •Patient not receiving a biologic agent, or receiving biologic agent <24weeks
- •Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
- •Has previously used DUOBRII
研究组 & 干预措施
Open Label Duobrii
Experimental
Duobrii QD
干预措施: Duobrii (Drug)
结局指标
主要结局
Body surface area improvement
时间窗: 8 weeks
body surface area determined by palm method where 1 palm is equivalent to 1%
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisPsoriasisNCT02931838Bristol-Myers Squibb268
已完成
不适用
Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.Plaque PsoriasisNCT05046899Biocool AB25
已完成
4 期
Vascular Inflammation in Psoriasis Trial (The VIP Trial)PsoriasisCardiovascular DiseaseNCT01553058University of Pennsylvania97
Unknown
1 期
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118Plaque PsoriasisNCT01670513Dow Pharmaceutical Sciences60
已完成
3 期
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)PsoriasisNCT00687401Merck Sharp & Dohme LLC215